Detalles de la búsqueda
1.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33863913
2.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 26(15): 3947-3957, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32312891
3.
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
Clin Cancer Res
; 26(16): 4242-4249, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234755
4.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066505
5.
PSI's Pharmaceutical Statistics Journal Club.
Pharm Stat
; 11(3): 193, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22535538
Resultados
1 -
5
de 5
1
Próxima >
>>